Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Adaptive designs for sequential treatment allocation / / Alessandro Baldi Antognini, University of Bologna, Italy, Alessandra Giovagnoli, University of Bologna, Italy
| Adaptive designs for sequential treatment allocation / / Alessandro Baldi Antognini, University of Bologna, Italy, Alessandra Giovagnoli, University of Bologna, Italy |
| Autore | Antognini Alessandro Baldi |
| Edizione | [1st edition] |
| Pubbl/distr/stampa | Boca Raton, Florida : , : CRC Press, , [2015] |
| Descrizione fisica | 1 online resource (210 p.) |
| Disciplina |
615.1072
615.10724 |
| Collana |
Chapman & Hall/CRC Biostatistics Series
Chapman & Hall Book |
| Soggetto topico | Adaptive sampling (Statistics) |
| ISBN | 0-429-08878-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Contents; List of Figures; List of Tables; Preface; Acknowledgments; Introduction; Chapter 1: Fundamentals and preliminary results; Chapter 2: Randomization procedures that are functions of the past allocations; Chapter 3: Randomization procedures that depend on the responses; Chapter 4: Multipurpose adaptive designs: Step-by-step procedures; Chapter 5: Multipurpose adaptive designs: Constrained and combined optimality; Chapter 6: Randomization procedures that depend on the covariates; Appendix A: Optimal designs; Appendix B: Bayesian approaches in adaptive designs; Bibliography
Back Cover |
| Record Nr. | UNINA-9910788023503321 |
Antognini Alessandro Baldi
|
||
| Boca Raton, Florida : , : CRC Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Adaptive designs for sequential treatment allocation / / Alessandro Baldi Antognini, University of Bologna, Italy, Alessandra Giovagnoli, University of Bologna, Italy
| Adaptive designs for sequential treatment allocation / / Alessandro Baldi Antognini, University of Bologna, Italy, Alessandra Giovagnoli, University of Bologna, Italy |
| Autore | Antognini Alessandro Baldi |
| Edizione | [1st edition] |
| Pubbl/distr/stampa | Boca Raton, Florida : , : CRC Press, , [2015] |
| Descrizione fisica | 1 online resource (210 p.) |
| Disciplina |
615.1072
615.10724 |
| Collana |
Chapman & Hall/CRC Biostatistics Series
Chapman & Hall Book |
| Soggetto topico | Adaptive sampling (Statistics) |
| ISBN | 0-429-08878-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Contents; List of Figures; List of Tables; Preface; Acknowledgments; Introduction; Chapter 1: Fundamentals and preliminary results; Chapter 2: Randomization procedures that are functions of the past allocations; Chapter 3: Randomization procedures that depend on the responses; Chapter 4: Multipurpose adaptive designs: Step-by-step procedures; Chapter 5: Multipurpose adaptive designs: Constrained and combined optimality; Chapter 6: Randomization procedures that depend on the covariates; Appendix A: Optimal designs; Appendix B: Bayesian approaches in adaptive designs; Bibliography
Back Cover |
| Record Nr. | UNINA-9910812360803321 |
|
Antognini Alessandro Baldi
|
||
| Boca Raton, Florida : , : CRC Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in drug research
| Advances in drug research |
| Pubbl/distr/stampa | London, : Academic Press |
| Disciplina | 615.1072 |
| ISSN | 0065-2490 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008886590403321 |
| London, : Academic Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
BioNMR in drug research [[electronic resource] /] / edited by Oliver Zerbe
| BioNMR in drug research [[electronic resource] /] / edited by Oliver Zerbe |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2003 |
| Descrizione fisica | 1 online resource (514 p.) |
| Disciplina |
615.1072
615/.19 |
| Altri autori (Persone) | ZerbeOliver |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Pharmaceutical chemistry
Nuclear magnetic resonance spectroscopy |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-52051-5
9786610520510 3-527-60542-8 3-527-60066-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BioNMR in Drug Research; Contents; Preface; Foreword; List of Authors; List of Abbreviations; Part I: Basic Techniques; 1 Modern Methods for the Expression of Proteins in Isotopically Enriched Form; 1.1 Introduction; 1.2 Isotope-Labeled Proteins from Hydrolyzates of the Green Alga Scenedesmus obliquus; 1.2.1 Production of Isotope-Labeled Algal Hydrolyzates; 1.2.2 Adaptation of the Protein Overproducer to the Algal Medium; 1.2.3 Preparation of Homogenously Isotope-Labeled Protein by Fermentation on Algal Media; 1.2.4 Amino Acid-Type Specific Labeling
1.2.5 Mass Spectrometric Analysis of the Labeled Amino Acids1.3 Selective Labeling Schemes; 1.3.1 Reverse-Labeling Schemes; 1.3.1.1 Selective Protonation of Methyl Groups in (2)H-Labeled Proteins; 1.3.1.2 Structure Determination of Selectively Methyl Protonated Proteins; 1.3.1.3 Introducting (1)H,(12)C Aromatic Residues into Otherwise (13)C Uniformly Labeled Proteins; 1.3.1.4 Backbone-Labeled Proteins; 1.3.2 Selective (13)C Methyl Group Labeling; 1.4 Intein-Based Protein Engineering for NMR Spectroscopy; 1.4.1 Segmental Labeling of Proteins 1.4.1.1 Intein-Mediated Protein Ligation (IPL)/Expressed Protein Ligation (EPL) using the IMPACT System1.4.1.2 Reconstitution of Split Inteins; 1.4.2 Stabilizing Proteins by Intein-Mediated Backbone Cyclization; 1.4.2.1 In vitro Cyclization of Proteins; 1.4.2.2 In vivo Cyclization; 1.4.2.3 Stability Enhancement by Backbone Cyclization; 1.5 Alternatives to E. coli Expression Systems; 1.5.1 Expression Vectors; 1.5.1.1 Halobacterium salinarum; 1.5.1.2 Saccharomyces cerevisiae; 1.5.1.3 Schizosaccharomyces pombe; 1.5.1.4 Pichia pastoris; 1.5.1.5 Baculovirus; 1.5.1.6 Transient Mammalian Expression 1.5.1.7 Stable Mammalian Expression1.5.1.8 Viral Vectors; 1.5.2 Comparison of Expression Systems; 1.5.3 Isotope Labeling and NMR; 1.5.4 Target Proteins; 1.6 The Use of Cell-Free Protein Expression for NMR Analysis; 1.6.1 The Cell-Free Protein Expression Systems RTS; 1.6.2 From PCR Product to (15)N-Labeled Protein; 1.6.3 Discussion and Outlook; 1.7 References; 2 Structure Calculation Using Automated Techniques; 2.1 Introduction; 2.2 Conformational Constraints for NMR Structure Calculations; 2.2.1 Constraints from Covalent Structure; 2.2.2 Steric Repulsion 2.2.3 Distance Constraints from Nuclear Overhauser Effects2.2.4 Hydrogen Bond Distance Constraints; 2.2.5 Torsion Angle Constraints from Chemical Shifts; 2.2.6 Torsion Angle Constraints from Scalar Coupling Constants; 2.2.7 Orientation Constraints; 2.3 Structure Calculation Algorithms; 2.3.1 Simulated Annealing by Molecular Dynamics Simulation in Cartesian Space; 2.3.2 Torsion Angle Dynamics; 2.4 Automated NOESY Assignment; 2.4.1 The NOESY Assignment Problem; 2.4.2 Semi-Automatic Methods; 2.4.3 General Principles of Automatic NOESY Assignment; 2.4.4 Requirements on Input Data 2.4.5 Overview of Algorithms |
| Record Nr. | UNINA-9910146242503321 |
| Weinheim, : Wiley-VCH, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
BioNMR in drug research [[electronic resource] /] / edited by Oliver Zerbe
| BioNMR in drug research [[electronic resource] /] / edited by Oliver Zerbe |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2003 |
| Descrizione fisica | 1 online resource (514 p.) |
| Disciplina |
615.1072
615/.19 |
| Altri autori (Persone) | ZerbeOliver |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Pharmaceutical chemistry
Nuclear magnetic resonance spectroscopy |
| ISBN |
1-280-52051-5
9786610520510 3-527-60542-8 3-527-60066-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BioNMR in Drug Research; Contents; Preface; Foreword; List of Authors; List of Abbreviations; Part I: Basic Techniques; 1 Modern Methods for the Expression of Proteins in Isotopically Enriched Form; 1.1 Introduction; 1.2 Isotope-Labeled Proteins from Hydrolyzates of the Green Alga Scenedesmus obliquus; 1.2.1 Production of Isotope-Labeled Algal Hydrolyzates; 1.2.2 Adaptation of the Protein Overproducer to the Algal Medium; 1.2.3 Preparation of Homogenously Isotope-Labeled Protein by Fermentation on Algal Media; 1.2.4 Amino Acid-Type Specific Labeling
1.2.5 Mass Spectrometric Analysis of the Labeled Amino Acids1.3 Selective Labeling Schemes; 1.3.1 Reverse-Labeling Schemes; 1.3.1.1 Selective Protonation of Methyl Groups in (2)H-Labeled Proteins; 1.3.1.2 Structure Determination of Selectively Methyl Protonated Proteins; 1.3.1.3 Introducting (1)H,(12)C Aromatic Residues into Otherwise (13)C Uniformly Labeled Proteins; 1.3.1.4 Backbone-Labeled Proteins; 1.3.2 Selective (13)C Methyl Group Labeling; 1.4 Intein-Based Protein Engineering for NMR Spectroscopy; 1.4.1 Segmental Labeling of Proteins 1.4.1.1 Intein-Mediated Protein Ligation (IPL)/Expressed Protein Ligation (EPL) using the IMPACT System1.4.1.2 Reconstitution of Split Inteins; 1.4.2 Stabilizing Proteins by Intein-Mediated Backbone Cyclization; 1.4.2.1 In vitro Cyclization of Proteins; 1.4.2.2 In vivo Cyclization; 1.4.2.3 Stability Enhancement by Backbone Cyclization; 1.5 Alternatives to E. coli Expression Systems; 1.5.1 Expression Vectors; 1.5.1.1 Halobacterium salinarum; 1.5.1.2 Saccharomyces cerevisiae; 1.5.1.3 Schizosaccharomyces pombe; 1.5.1.4 Pichia pastoris; 1.5.1.5 Baculovirus; 1.5.1.6 Transient Mammalian Expression 1.5.1.7 Stable Mammalian Expression1.5.1.8 Viral Vectors; 1.5.2 Comparison of Expression Systems; 1.5.3 Isotope Labeling and NMR; 1.5.4 Target Proteins; 1.6 The Use of Cell-Free Protein Expression for NMR Analysis; 1.6.1 The Cell-Free Protein Expression Systems RTS; 1.6.2 From PCR Product to (15)N-Labeled Protein; 1.6.3 Discussion and Outlook; 1.7 References; 2 Structure Calculation Using Automated Techniques; 2.1 Introduction; 2.2 Conformational Constraints for NMR Structure Calculations; 2.2.1 Constraints from Covalent Structure; 2.2.2 Steric Repulsion 2.2.3 Distance Constraints from Nuclear Overhauser Effects2.2.4 Hydrogen Bond Distance Constraints; 2.2.5 Torsion Angle Constraints from Chemical Shifts; 2.2.6 Torsion Angle Constraints from Scalar Coupling Constants; 2.2.7 Orientation Constraints; 2.3 Structure Calculation Algorithms; 2.3.1 Simulated Annealing by Molecular Dynamics Simulation in Cartesian Space; 2.3.2 Torsion Angle Dynamics; 2.4 Automated NOESY Assignment; 2.4.1 The NOESY Assignment Problem; 2.4.2 Semi-Automatic Methods; 2.4.3 General Principles of Automatic NOESY Assignment; 2.4.4 Requirements on Input Data 2.4.5 Overview of Algorithms |
| Record Nr. | UNINA-9910830427103321 |
| Weinheim, : Wiley-VCH, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Carbon monoxide in drug discovery : basics, pharmacology, and therapeutic potential / / edited by Leo E. Otterbein, Binghe Wang
| Carbon monoxide in drug discovery : basics, pharmacology, and therapeutic potential / / edited by Leo E. Otterbein, Binghe Wang |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] |
| Descrizione fisica | 1 online resource (1005 pages) |
| Disciplina | 615.1072 |
| Collana | Wiley Series in Drug Discovery and Development Ser. |
| Soggetto topico | Drugs - Research |
| ISBN |
1-119-78343-7
1-119-78342-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Carbon Monoxide in Drug Discovery -- Contents -- List of Contributors -- Preface: Carbon Monoxide: Promises and Challenges in Its Pharmaceutical Development -- Section I General Background and Physiological Actions -- 1 Endogenous CO Production in Sickness and in Health -- 2 Molecular Mechanisms of Actions for CO: An Overview -- 3 Pharmacokinetic Characteristics of Carbon Monoxide -- 4 Carbon Monoxide and Energy Metabolism -- 5 Role of CO in Circadian Clock -- 6 Carbon Monoxide and Mitochondria -- 7 Carbon Monoxide, Oxygen, and Pseudohypoxia -- 8 Nitric Oxide in Human Physiology: Production, Regulation, and Interaction with Carbon Monoxide Signaling -- 9 When Carbon Monoxide Meets Hydrogen Sulfide -- 10 Biliverdin and Bilirubin as Parallel Products of CO Formation: Not Just Bystanders -- Section II Delivery Forms -- 11 Delivery Systems and Noncarrier Formulations -- 12 Metal-Based Carbon Monoxide-Releasing Molecules (CO-RMs) as Pharmacologically Active Therapeutics -- 13 Organic CO Donors that Rely on Photolysis for CO Release -- 14 Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions -- 15 Targeted Delivery of Carbon Monoxide -- 16 Anesthesia-Related Carbon Monoxide Exposure -- 17 Natural Products that Generate Carbon Monoxide: Chemistry and Nutritional Implications -- Section III Carbon Monoxide Sensing and Scavenging -- 18 Fluorescent Probes for Intracellular Carbon Monoxide Detection -- Section IV Therapeutic Applications -- 19 CO in Solid Organ Transplantation -- 20 Carbon Monoxide in Lung Injury and Disease -- 21 Carbon Monoxide in Acute Brain Injury and Brain Protection -- 22 CO as a Protective Mediator of Liver Injury: The Role of PERK in HO-1/CO-Mediated Maintenance of Cellular Homeostasis in the Liver -- 23 CO and Cancer -- 24 CO and Diabetes -- 25 Carbon Monoxide and Acute Kidney Injury.
26 CO as an Antiplatelet Agent: An Energy Metabolism Perspective -- 27 CO in Gastrointestinal Physiology and Protection -- 28 Carbon Monoxide and Sickle Cell Disease -- 29 CO and Pain Management -- 30 Clinical Trials of Low-Dose Carbon Monoxide -- Index -- EULA. |
| Record Nr. | UNINA-9910573096703321 |
| Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Carbon monoxide in drug discovery : basics, pharmacology, and therapeutic potential / / edited by Leo E. Otterbein, Binghe Wang
| Carbon monoxide in drug discovery : basics, pharmacology, and therapeutic potential / / edited by Leo E. Otterbein, Binghe Wang |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] |
| Descrizione fisica | 1 online resource (1005 pages) |
| Disciplina | 615.1072 |
| Collana | Wiley Series in Drug Discovery and Development |
| Soggetto topico | Drugs - Research |
| ISBN |
1-119-78341-0
1-119-78343-7 1-119-78342-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Carbon Monoxide in Drug Discovery -- Contents -- List of Contributors -- Preface: Carbon Monoxide: Promises and Challenges in Its Pharmaceutical Development -- Section I General Background and Physiological Actions -- 1 Endogenous CO Production in Sickness and in Health -- 2 Molecular Mechanisms of Actions for CO: An Overview -- 3 Pharmacokinetic Characteristics of Carbon Monoxide -- 4 Carbon Monoxide and Energy Metabolism -- 5 Role of CO in Circadian Clock -- 6 Carbon Monoxide and Mitochondria -- 7 Carbon Monoxide, Oxygen, and Pseudohypoxia -- 8 Nitric Oxide in Human Physiology: Production, Regulation, and Interaction with Carbon Monoxide Signaling -- 9 When Carbon Monoxide Meets Hydrogen Sulfide -- 10 Biliverdin and Bilirubin as Parallel Products of CO Formation: Not Just Bystanders -- Section II Delivery Forms -- 11 Delivery Systems and Noncarrier Formulations -- 12 Metal-Based Carbon Monoxide-Releasing Molecules (CO-RMs) as Pharmacologically Active Therapeutics -- 13 Organic CO Donors that Rely on Photolysis for CO Release -- 14 Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions -- 15 Targeted Delivery of Carbon Monoxide -- 16 Anesthesia-Related Carbon Monoxide Exposure -- 17 Natural Products that Generate Carbon Monoxide: Chemistry and Nutritional Implications -- Section III Carbon Monoxide Sensing and Scavenging -- 18 Fluorescent Probes for Intracellular Carbon Monoxide Detection -- Section IV Therapeutic Applications -- 19 CO in Solid Organ Transplantation -- 20 Carbon Monoxide in Lung Injury and Disease -- 21 Carbon Monoxide in Acute Brain Injury and Brain Protection -- 22 CO as a Protective Mediator of Liver Injury: The Role of PERK in HO-1/CO-Mediated Maintenance of Cellular Homeostasis in the Liver -- 23 CO and Cancer -- 24 CO and Diabetes -- 25 Carbon Monoxide and Acute Kidney Injury.
26 CO as an Antiplatelet Agent: An Energy Metabolism Perspective -- 27 CO in Gastrointestinal Physiology and Protection -- 28 Carbon Monoxide and Sickle Cell Disease -- 29 CO and Pain Management -- 30 Clinical Trials of Low-Dose Carbon Monoxide -- Index -- EULA. |
| Record Nr. | UNINA-9910678097703321 |
| Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery and development . Volume 2 Drug development [[electronic resource] /] / edited by Mukund S. Chorghade
| Drug discovery and development . Volume 2 Drug development [[electronic resource] /] / edited by Mukund S. Chorghade |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (401 p.) |
| Disciplina |
615.1072
615.19 |
| Altri autori (Persone) | ChorghadeMukund S (Mukund Shankar) |
| Soggetto topico |
Drug development
Pharmacology |
| ISBN |
1-281-00213-5
9786611002138 0-470-08522-3 0-470-08521-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; Contributors; Preface; 17 Bioactive Molecules in Medicinal Plants: A Perspective on Their Therapeutic Action; 17.1 Introduction; 17.2 Evolutionary Relationships Among Plants and Humans; 17.3 Traditional Wisdom; 17.4 Unique Libraries for Plants; 17.5 Drugs and Bioactive Molecules from Plants; 17.6 Synergism in Herbal Formulations; 17.7 Interactions Between Modern Drugs and Natural Products; 17.8 Bioavailability and Bioefficacy Enhancers; 17.9 Combination Therapies in Modern Drugs; 17.10 Role of Developments in Technologies and Analytical Tools
17.10.1 Developments in Separation Technologies17.10.2 Developments in Combined Techniques and Advanced Technologies; 17.10.3 Molecular Farming and Bioengineering of Medicinal Plants; 17.10.4 High-Throughput Screening of Natural Products; 17.11 Herbal Medicine: The Best Possible Route to Health Care; References; 18 Natural Products as an Inspiration for the Discovery of New High-Throughput Chemical Synthesis Tools; 18.1 Introduction; 18.2 Solid-Supported Reagents as Tools in Natural Product Synthesis; 18.3 Multistep Use of Supported Reagents in Natural Product Synthesis; 18.4 Conclusions References19 Insulin Sensitizers: Emerging Therapeutics; 19.1 Introduction; 19.2 Therapeutic Interventions; 19.3 Discovery of Insulin Sensitizers; 19.4 Journey Toward New Drugs; 19.5 Conclusions; References; 20 Criteria for Industrial Readiness of Chiral Catalysis Technology for the Synthesis of Pharmaceuticals; 20.1 Introduction; 20.2 Criteria for Technology Readiness; 20.3 Examples of Industrially Ready Chiral Catalytic Technologies and Their Application; 20.3.1 Lipase Bioresolution: Ethyl 3-Amino-3-Phenylpropionate; 20.3.2 Aminoacylase Bioresolution of N-Acylamino Acids 20.3.3 Asymmetric Hydrogenation of Prochiral Olefins by Rhodium-DuPhos Catalysts20.3.4 Asymmetric Hydrogenation of Prochiral Ketones by Ruthenium-Biphosphine-Diamine Catalysts; 20.3.5 Asymmetric Hydroformylation with Rhodium-Phosphite Catalysts; 20.3.6 Asymmetric Allylic Substitution with Palladium-Based Catalysts; 20.4 How Industrially Ready Technology Can Deliver Commercial Advantages; 20.5 Conclusions; References; 21 Enantioselective Synthesis of Propargyl Alcohols as Multifunctional Synthons; 21.1 Introduction; 21.2 Asymmetric Reduction of Prochiral α, β-Alkynyl Ketones 21.3 Addition of Acetylenic Anion to Carbonyl Carbon21.4 Desymmetrization and Enzymatic Strategies for Chiral Propargyl Alcohol Synthesis; 21.5 β-Elimination Strategy and Miscellaneous Approaches; 21.6 Conclusions; References; 22 Carbohydrates: From Chirons to Mimics; 22.1 Introduction; 22.2 Synthetic Strategies for C-Glycosides; 22.3 Synthetic Strategies for Carbon-Linked Disaccharides and Pseudosaccharides; References; 23 Meeting the Challenges of Process Development and Scale-up of Active Pharmaceutical Ingredients; 23.1 Introduction; 23.1.1 Drug Development in the Pharmaceutical Industry 23.1.2 Challenges in Developing and Scaling Up Chemical Processes |
| Record Nr. | UNINA-9910143983503321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery and development . Volume 2 Drug development / / edited by Mukund S. Chorghade
| Drug discovery and development . Volume 2 Drug development / / edited by Mukund S. Chorghade |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (401 p.) |
| Disciplina |
615.1072
615.19 |
| Altri autori (Persone) | ChorghadeMukund S (Mukund Shankar) |
| Soggetto topico |
Drug development
Pharmacology |
| ISBN |
1-281-00213-5
9786611002138 0-470-08522-3 0-470-08521-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; Contributors; Preface; 17 Bioactive Molecules in Medicinal Plants: A Perspective on Their Therapeutic Action; 17.1 Introduction; 17.2 Evolutionary Relationships Among Plants and Humans; 17.3 Traditional Wisdom; 17.4 Unique Libraries for Plants; 17.5 Drugs and Bioactive Molecules from Plants; 17.6 Synergism in Herbal Formulations; 17.7 Interactions Between Modern Drugs and Natural Products; 17.8 Bioavailability and Bioefficacy Enhancers; 17.9 Combination Therapies in Modern Drugs; 17.10 Role of Developments in Technologies and Analytical Tools
17.10.1 Developments in Separation Technologies17.10.2 Developments in Combined Techniques and Advanced Technologies; 17.10.3 Molecular Farming and Bioengineering of Medicinal Plants; 17.10.4 High-Throughput Screening of Natural Products; 17.11 Herbal Medicine: The Best Possible Route to Health Care; References; 18 Natural Products as an Inspiration for the Discovery of New High-Throughput Chemical Synthesis Tools; 18.1 Introduction; 18.2 Solid-Supported Reagents as Tools in Natural Product Synthesis; 18.3 Multistep Use of Supported Reagents in Natural Product Synthesis; 18.4 Conclusions References19 Insulin Sensitizers: Emerging Therapeutics; 19.1 Introduction; 19.2 Therapeutic Interventions; 19.3 Discovery of Insulin Sensitizers; 19.4 Journey Toward New Drugs; 19.5 Conclusions; References; 20 Criteria for Industrial Readiness of Chiral Catalysis Technology for the Synthesis of Pharmaceuticals; 20.1 Introduction; 20.2 Criteria for Technology Readiness; 20.3 Examples of Industrially Ready Chiral Catalytic Technologies and Their Application; 20.3.1 Lipase Bioresolution: Ethyl 3-Amino-3-Phenylpropionate; 20.3.2 Aminoacylase Bioresolution of N-Acylamino Acids 20.3.3 Asymmetric Hydrogenation of Prochiral Olefins by Rhodium-DuPhos Catalysts20.3.4 Asymmetric Hydrogenation of Prochiral Ketones by Ruthenium-Biphosphine-Diamine Catalysts; 20.3.5 Asymmetric Hydroformylation with Rhodium-Phosphite Catalysts; 20.3.6 Asymmetric Allylic Substitution with Palladium-Based Catalysts; 20.4 How Industrially Ready Technology Can Deliver Commercial Advantages; 20.5 Conclusions; References; 21 Enantioselective Synthesis of Propargyl Alcohols as Multifunctional Synthons; 21.1 Introduction; 21.2 Asymmetric Reduction of Prochiral α, β-Alkynyl Ketones 21.3 Addition of Acetylenic Anion to Carbonyl Carbon21.4 Desymmetrization and Enzymatic Strategies for Chiral Propargyl Alcohol Synthesis; 21.5 β-Elimination Strategy and Miscellaneous Approaches; 21.6 Conclusions; References; 22 Carbohydrates: From Chirons to Mimics; 22.1 Introduction; 22.2 Synthetic Strategies for C-Glycosides; 22.3 Synthetic Strategies for Carbon-Linked Disaccharides and Pseudosaccharides; References; 23 Meeting the Challenges of Process Development and Scale-up of Active Pharmaceutical Ingredients; 23.1 Introduction; 23.1.1 Drug Development in the Pharmaceutical Industry 23.1.2 Challenges in Developing and Scaling Up Chemical Processes |
| Record Nr. | UNINA-9910677468603321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery and development / edited by Michael Williams and Jeffrey B. Malick
| Drug discovery and development / edited by Michael Williams and Jeffrey B. Malick |
| Pubbl/distr/stampa | Clifton : Humana Press, 1987 |
| Descrizione fisica | XVIII, 447 p. : ill. ; 24 cm |
| Disciplina | 615.1072 |
| Collana | Contemporary biomedicine |
| Soggetto non controllato |
Tecnica farmaceutica
Industria farmaceutica - Ricerca e sviluppo |
| ISBN | 0-89603-108-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008317830403321 |
| Clifton : Humana Press, 1987 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
